Pluvicto Safety and Supportive Care: PSMAddition Trial Insights
- Understanding the unique safety profile of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is crucial for pharmacists involved in the care of patients with prostate cancer.
- The PSMAddition trial has provided valuable insights into the safety profile of Pluvicto.
- These on-target effects manifest as dryness of the mouth and various gastrointestinal disturbances, including nausea, vomiting, constipation, and diarrhea.
“`html
Table of Contents
Understanding the unique safety profile of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is crucial for pharmacists involved in the care of patients with prostate cancer. This article details key tolerability findings from the PSMAddition trial,focusing on hematologic toxicity,renal effects,and necessary supportive care measures.
Understanding PSMAddition Safety Findings
The PSMAddition trial has provided valuable insights into the safety profile of Pluvicto. While generally well-tolerated, pharmacists must be aware of specific adverse events and proactively manage potential complications. Constitutional symptoms, especially fatigue, are frequently reported across all studies. However, the most notable adverse events are often linked to “on-target, off-tumor” effects, stemming from PSMA expression in tissues beyond the prostate cancer cells.
These on-target effects manifest as dryness of the mouth and various gastrointestinal disturbances, including nausea, vomiting, constipation, and diarrhea. Pharmacists should counsel patients on strategies to manage these symptoms, such as frequent hydration, dietary adjustments, and antiemetics as needed.
Renal Effects: A Critical Consideration
The kidney is identified as an at-risk organ due to PSMA expression in the proximal renal tubule and the renally excreted nature of the drug. While phase 3 studies haven’t shown important renal failure to date, vigilance is paramount. The current safety follow-up, while the longest available, only extends to approximately two years for the primary efficacy endpoint, meaning late-onset renal effects remain a possibility.
Patients with pre-existing renal dysfunction require particularly close monitoring. Impaired renal clearance leads to prolonged circulation of the radiopharmaceutical, possibly increasing exposure and risk. According to SNMMI and EANM criteria for mCRPC, pluvicto can still be administered to patients with a creatinine clearance around 30, but increased monitoring for myelosuppression is crucial in these cases.
Hematologic toxicity: A Distinct Pattern
Pluvicto can induce myelosuppression, but the pattern differs from that typically observed with chemotherapy. The nadir, or lowest point in blood cell counts, generally occurs 3 to 4 weeks post-management. Anemia is the most common hematologic toxicity, followed by neutropenia and thrombocytopenia.
Interestingly, Pluvicto tends to cause more thrombocytopenia and less neutropenia compared to traditional chemotherapy regimens.Though, these events are usually grade 1 or 2 in severity. Patients initiating treatment with pre-existing low platelet counts or other hematologic abnormalities require careful monitoring before each cycle to ensure safe continuation of therapy.
| Hematologic Toxicity | Typical Timing of nadir | Relative Incidence (vs. Chemotherapy) |
|---|---|---|
| Anemia | 3-4 weeks post-administration | Comparable |
| Neutropenia | 3-4 weeks post-administration |